- Basal analogues of human insulin of super long-term effect
- It is a recombinant human insulin where residual fatty acid is linked to lysine through a linker
- Provides for an even stable sugar reducing effect lasting for over 42 hours and low intraindividual variability
- Produced in two concentrations: U100, U200
- The effect starts in 30–90 min after subcutaneous injection
- The effect lasts for 42 hours
Development of analogues portfolio Insulin Degludec
GEROPHARM is developing a full line of insulin bio analogues that are at different stages of studying.
Advantages of bio analogues:
- less variable, more stable effect;
- economic efficiency.
Name of
the drug
the drug
Stage:
Pharmaceut. Development
Preclinical Trials
Clinical Trials
1
2
3
registration
Insulin Degludec
2018 - CityAD - All rights reserved
Made in 